FilingSEC EDGAR8-K
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in TP53-Mutated AML Patients
· SEC accepted
Filing content
Aptevo Therapeutics announced that its mipletamig triplet therapy achieved a 93% clinical benefit rate in 13 out of 14 evaluable patients with difficult-to-treat TP53-mutated acute myeloid leukemia (AML).
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…